CONTE, Pierfranco
 Distribuzione geografica
Continente #
NA - Nord America 3.229
EU - Europa 1.147
AS - Asia 550
AF - Africa 38
SA - Sud America 24
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.012
Nazione #
US - Stati Uniti d'America 3.167
IT - Italia 390
CN - Cina 290
DE - Germania 249
FR - Francia 198
GB - Regno Unito 71
VN - Vietnam 62
CA - Canada 51
IN - India 50
SE - Svezia 40
RU - Federazione Russa 25
JP - Giappone 24
ES - Italia 23
AU - Australia 22
IE - Irlanda 21
UA - Ucraina 18
ZA - Sudafrica 16
NL - Olanda 15
AE - Emirati Arabi Uniti 14
TW - Taiwan 14
TR - Turchia 13
CZ - Repubblica Ceca 12
EG - Egitto 11
FI - Finlandia 11
MX - Messico 10
RO - Romania 10
AM - Armenia 9
CL - Cile 9
IQ - Iraq 9
PK - Pakistan 9
GR - Grecia 8
BR - Brasile 7
PT - Portogallo 7
HU - Ungheria 6
PH - Filippine 6
PL - Polonia 6
SY - Repubblica araba siriana 6
BA - Bosnia-Erzegovina 5
DK - Danimarca 5
HK - Hong Kong 5
ID - Indonesia 5
IR - Iran 5
SA - Arabia Saudita 5
AR - Argentina 4
BE - Belgio 4
HR - Croazia 4
KR - Corea 4
LT - Lituania 4
LY - Libia 4
AT - Austria 3
NG - Nigeria 3
PE - Perù 3
UZ - Uzbekistan 3
CH - Svizzera 2
IL - Israele 2
KW - Kuwait 2
LB - Libano 2
LV - Lettonia 2
ME - Montenegro 2
MY - Malesia 2
NO - Norvegia 2
SG - Singapore 2
TH - Thailandia 2
YE - Yemen 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
CO - Colombia 1
CY - Cipro 1
DZ - Algeria 1
EU - Europa 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
MD - Moldavia 1
MV - Maldive 1
MZ - Mozambico 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.012
Città #
Fairfield 488
Houston 301
Ashburn 265
Woodbridge 233
Seattle 206
Santa Cruz 164
Cambridge 156
Buffalo 135
Ann Arbor 125
Wilmington 122
Beijing 98
San Diego 70
Des Moines 65
Dong Ket 60
Modena 46
Mountain View 40
Chicago 36
Stockholm 36
Milan 33
Chandler 32
Boardman 29
Las Vegas 27
Paris 27
Los Angeles 25
Wuhan 25
Nanjing 23
Nürnberg 23
Ottawa 23
Rome 22
Dublin 21
Bengaluru 18
University Park 17
Toronto 16
Phoenix 15
Shanghai 15
Muizenberg 14
Fuzhou 13
Hangzhou 13
Hebei 13
Silver Spring 13
Helsinki 11
New York 11
Riva 11
Guangzhou 10
Padova 10
San Francisco 10
Bologna 9
Collegeville 9
Atlanta 8
Dallas 8
Southend 8
Brisbane 7
Clearwater 7
Genoa 7
Hyderabad 7
Lake Forest 7
Taipei 7
Turin 7
Henderson 6
Jinan 6
Melbourne 6
Munich 6
Yerevan 6
Athens 5
Aydin 5
Boulder 5
Büdelsdorf 5
Cadeo 5
Council Bluffs 5
Dongguan 5
London 5
Mexico 5
Nanchang 5
Reggio Emilia 5
Sarajevo 5
Sassari 5
Alexandria 4
Barcelona 4
Bremen 4
Bucharest 4
Columbus 4
Delhi 4
Duncan 4
Falkenstein 4
Frankfurt am Main 4
Granada 4
Groningen 4
Istanbul 4
Leawood 4
Ningbo 4
Pittsburgh 4
Shinjuku 4
Tripoli 4
Yellow Springs 4
Zaragoza 4
Boston 3
Cairo 3
Cardiff 3
Castelfidardo 3
Cedar Knolls 3
Totale 3.443
Nome #
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities, file e31e124c-0965-987f-e053-3705fe0a095a 428
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer., file e31e124d-7808-987f-e053-3705fe0a095a 315
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management, file e31e124d-7fd3-987f-e053-3705fe0a095a 307
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB), file e31e124d-7671-987f-e053-3705fe0a095a 289
Immune characterization of breast cancer metastases: prognostic implications., file e31e124d-5d08-987f-e053-3705fe0a095a 258
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer, file e31e124d-9653-987f-e053-3705fe0a095a 240
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial., file e31e124d-7fd1-987f-e053-3705fe0a095a 230
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood, file e31e124c-0052-987f-e053-3705fe0a095a 224
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma, file e31e124d-9655-987f-e053-3705fe0a095a 216
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial ., file e31e124d-cbc5-987f-e053-3705fe0a095a 195
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing, file e31e124b-5969-987f-e053-3705fe0a095a 193
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus, file e31e124d-734b-987f-e053-3705fe0a095a 190
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer., file e31e124d-ce9b-987f-e053-3705fe0a095a 169
Triple-negative breast cancer: current management and future options., file e31e124e-1a5e-987f-e053-3705fe0a095a 165
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA, file e31e124d-35ff-987f-e053-3705fe0a095a 159
Controversies of chemotherapy for the treatment of metastatic breast cancer., file e31e124e-154d-987f-e053-3705fe0a095a 156
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis, file e31e124d-7fcf-987f-e053-3705fe0a095a 143
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial., file e31e124d-cb11-987f-e053-3705fe0a095a 131
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY), file e31e124d-33f2-987f-e053-3705fe0a095a 122
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial, file e31e124f-ec08-987f-e053-3705fe0a095a 107
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y), file e31e124e-a41a-987f-e053-3705fe0a095a 105
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici, file e31e124a-97dc-987f-e053-3705fe0a095a 77
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER, file e31e124d-351c-987f-e053-3705fe0a095a 63
LOCAL RECURRENCE AFTER NEO-ADJUVANT CHEMOTHERAPY AND BREAST CONSERVING SURGERY, file e31e124d-2092-987f-e053-3705fe0a095a 62
Device for cell culture, file e31e124a-9d0c-987f-e053-3705fe0a095a 55
Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34+ cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support., file e31e124e-13ed-987f-e053-3705fe0a095a 31
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124f-89bb-987f-e053-3705fe0a095a 31
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis, file e31e124c-08f7-987f-e053-3705fe0a095a 29
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS, file e31e124d-30ab-987f-e053-3705fe0a095a 29
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO, file e31e124d-30e4-987f-e053-3705fe0a095a 29
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial, file e31e1250-9101-987f-e053-3705fe0a095a 28
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY., file e31e124e-9724-987f-e053-3705fe0a095a 27
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT, file e31e124d-223a-987f-e053-3705fe0a095a 25
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3704-987f-e053-3705fe0a095a 25
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA, file e31e124d-3016-987f-e053-3705fe0a095a 23
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS, file e31e124d-3017-987f-e053-3705fe0a095a 22
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS?, file e31e124d-223c-987f-e053-3705fe0a095a 19
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, file a6a3589d-4ddd-44e5-a9ef-7c7ce3bfc294 18
TAILORED MANAGEMENT OF ADVANCED BREAST CANCER: IS IT WORTH TO TAKE A BIOPSY OF METASTATIC SITES?, file e31e124d-223e-987f-e053-3705fe0a095a 18
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE, file e31e124d-3522-987f-e053-3705fe0a095a 18
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy., file 3171ff3b-9c3a-4cef-94ca-d122ec5822e0 17
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design., file 50125a79-d15f-4420-845a-4cba99984d1a 16
Primary systemic treatment of operable breast cancer with targeted agents, file e31e124d-32ca-987f-e053-3705fe0a095a 16
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE, file e31e124d-3519-987f-e053-3705fe0a095a 16
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY, file e31e124d-38aa-987f-e053-3705fe0a095a 14
TREATMENT OF EARLY HER2+ BREAST CANCER: ACHIEVEMENTS AND UNMET NEEDS, file e31e124d-2110-987f-e053-3705fe0a095a 10
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3075-987f-e053-3705fe0a095a 10
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)., file d230e624-2b64-483e-9d21-b703da38ed62 9
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial, file 1264406e-f2c7-4461-a784-fb6ee90d3d5f 8
Randomized controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from Mario Negri Institute of Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group., file 8103b041-9b3a-4467-bd2e-6598d7b76959 7
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial, file 4ad83630-2aa3-40ae-b6b0-34e1c313a502 6
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas, file e31e124b-ffe1-987f-e053-3705fe0a095a 6
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts, file bf213bec-1647-46b0-a203-20d776629dcd 5
Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety, file 2b111427-83d8-451a-84d8-ea5668bcec0f 4
Optimizing Bisphosphonate therapy in Oncology, file b49920bb-1658-454a-947c-65f70a425abf 4
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy, file b90eb385-8b45-4964-9e43-ab89a237165d 4
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials, file e31e124c-033f-987f-e053-3705fe0a095a 4
Muiticentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer, file ea68bfc8-2760-4af4-8e5f-bf4b2f296fda 4
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer, file 39f0de05-ed6f-4a67-97e0-9a8ce7eed0c5 3
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab, file dc88f2b3-59fc-468a-aee9-b7bc0c5becc2 3
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), file c0455a7d-75be-4e41-a009-fe11d544c62d 2
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer, file e31e124a-967d-987f-e053-3705fe0a095a 2
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria, file e31e124a-97da-987f-e053-3705fe0a095a 2
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer., file e31e124a-9c6a-987f-e053-3705fe0a095a 2
Heterogeneity of multipotent mesenchimal stromal cells: from stromal cells to stem cells and viceversa, file e31e124a-9f49-987f-e053-3705fe0a095a 2
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases, file e31e124a-9f52-987f-e053-3705fe0a095a 2
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies., file e31e124a-aba1-987f-e053-3705fe0a095a 2
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma, file e31e124a-acfd-987f-e053-3705fe0a095a 2
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact, file e31e124c-0494-987f-e053-3705fe0a095a 2
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study, file edcdd8de-215f-49c6-9abb-0985573f6c0d 2
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study, file f800e220-a4de-4bda-9cef-86eb5303726e 2
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients, file ff5e87e6-33f4-4094-9b20-ed07baf00572 2
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma, file 8e9fbe70-d335-4fe1-96b8-779cb8a1c805 1
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM, file e31e124a-9519-987f-e053-3705fe0a095a 1
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry, file e31e124a-9c7a-987f-e053-3705fe0a095a 1
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy, file e31e124a-9f5a-987f-e053-3705fe0a095a 1
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1, file e31e124a-a2cd-987f-e053-3705fe0a095a 1
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting, file e31e124a-a2cf-987f-e053-3705fe0a095a 1
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer, file e31e124a-af0f-987f-e053-3705fe0a095a 1
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis., file e31e124a-af9d-987f-e053-3705fe0a095a 1
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study, file e31e124b-2edd-987f-e053-3705fe0a095a 1
Timing for starting second line therapy in recurrent ovarian cancer., file e31e124b-2ee2-987f-e053-3705fe0a095a 1
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis, file e31e124b-3439-987f-e053-3705fe0a095a 1
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer, file e31e124d-766b-987f-e053-3705fe0a095a 1
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124d-80fe-987f-e053-3705fe0a095a 1
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion., file e31e124d-d8bd-987f-e053-3705fe0a095a 1
Totale 5.175
Categoria #
all - tutte 18.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.317


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019216 0 0 0 0 0 0 0 0 0 45 90 81
2019/2020807 57 44 30 71 79 77 100 83 96 57 64 49
2020/20211.119 58 70 68 78 81 75 128 153 61 149 105 93
2021/20221.260 112 172 144 148 117 38 67 61 56 53 206 86
2022/2023877 34 77 168 93 56 136 42 51 61 31 93 35
2023/2024605 25 30 49 43 53 47 136 108 75 39 0 0
Totale 5.175